NEW YORK (GenomeWeb News) – Shares of Sequenom soared in Tuesday trade, even though there appeared to be no news that would create such a surge in both its price and trading volume.

Sequenom finished Tuesday up 58 percent at $5.30 on the Nasdaq. More than 53 million shares traded hands on the day — nearly 10 times its average daily trading volume.

There was no news or filings with the US Securities and Exchange Commission that would account for the spike, leading to the usual rumors on various stock trading message boards that news could be on the way.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.